Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: A sign of exhausted adrenal reserve?

Critical Care

Volumn 6, Issue 5, 2002, Pages 434-438

  Beishuizen, Albertus ^a   Thijs, Lambertus G ^a   Vermes, István ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Adrenal insufficiency; Dehydroepiandrosterone sulphate; Hypothalamic pituitary adrenal axis; Multiple trauma; Sepsis

Indexed keywords

CORTICOTROPIN; DOPAMINE; HYDROCORTISONE; INTERLEUKIN 6; PRASTERONE; PRASTERONE SULFATE; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT;

ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL ILLNESS; DISEASE SEVERITY; DISSOCIATION; DRUG MEGADOSE; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MALE; MULTIPLE TRAUMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; SEPTIC SHOCK;

EID: 0036787216     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc1530     Document Type: Article

References (13)

1. Ebeling P, Koivisto VA: Physiological importance of dehydroepiandrosterone. Lancet 1994, 343:1479-1481.
2. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999, 341:1013-1020.
3. Oberbeck R, Dahlweid M, Koch R, van Griensven M, Emmendörfer A, Tscherne H, Pape HC: Dehydroepiandrosterone decreases mortality and improves cellular immune function during polymicrobial sepsis. Crit Care Med 2001, 29:380-384.
4. Achermann JC, Silverman BL: Dehydroepiandrosterone replacement for patients with adrenal insufficiency. Lancet 2001, 357:1381-1382.
5. Beishuizen A, Vermes I, Hylkema BS, Haanen C: Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet 1999, 353:1675-1676.
6. Beishuizen A, Thijs LG. Relative adrenal failure in intensive care: an identifiable problem requiring treatment? Best Pract Res Clin Endocrinol Metab 2001, 15:513-531.
7. Parker LN, Levin ER, Lifrak ET Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985, 60: 947-952.
8. Luppa P, Munker R, Nagel D, Weber M, Engelhardt D: Serum androgens in intensive-care patients: correlations with clinical findings. Clin Endocrinol (Oxf) 1991, 34:305-310.
9. Van den Berghe G, de Zegher F, Wouters P, Schetz M, Verwaest C, Ferdinande P, Lauwers P: Dehydroepiandrosterone sulphate in critical illness: effect of dopamine. Clin Endocrinol (Oxf) 1995, 43:457-463.
10. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J, Falk W, Lang B: Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998, 83:2012-2017.
11. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993, 77:1690-1694.
12. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999, 39:327-348.
13. Baulieu E-E. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metabol 1996, 81:3147-3151.